PMID- 14632588
OWN - NLM
STAT- MEDLINE
DCOM- 20040413
LR  - 20181130
IS  - 1060-0280 (Print)
IS  - 1060-0280 (Linking)
VI  - 37
IP  - 12
DP  - 2003 Dec
TI  - Tinzaparin: considerations for use in clinical practice.
PG  - 1831-40
AB  - OBJECTIVE: To evaluate the safety and effectiveness of tinzaparin for the 
      prevention and treatment of venous thromboembolism (VTE). DATA SOURCES: A MEDLINE 
      and PubMed database search (1980-December 2002) was conducted. Only articles 
      written in English were reviewed. STUDY SELECTION AND DATA EXTRACTION: Articles 
      reporting the safety, efficacy, and cost-effectiveness of tinzaparin in humans 
      were evaluated. Emphasis was placed on randomized, controlled trials. DATA 
      SYNTHESIS: Tinzaparin sodium is a low-molecular-weight heparin (LMWH) that exerts 
      its anticoagulant effect through inhibition of factors Xa and IIa and release of 
      tissue factor pathway inhibitor from the vascular epithelium. Tinzaparin is 
      indicated for treatment of acute symptomatic deep-vein thrombosis (DVT), with or 
      without pulmonary embolism. Clinical studies suggest that tinzaparin is also 
      effective for VTE prophylaxis, as well as other indications. Once-daily 
      subcutaneous tinzaparin is equally or more effective than intravenous 
      unfractionated heparin (UFH) for prevention and treatment of VTE, at least as 
      safe as UFH for bleeding complications, and requires little or no monitoring. No 
      dose "cap" is required for obese patients, and no initial dosing adjustments are 
      necessary in elderly and/or renally impaired patients, although some monitoring 
      is recommended. The few comparative data available suggest that tinzaparin 
      efficacy may be comparable to that of other LMWHs; more comparative studies are 
      needed. Pharmacoeconomic studies indicate a favorable cost-benefit ratio. 
      CONCLUSIONS: Tinzaparin is safe and effective for prevention and treatment of 
      DVT. Consistent once-daily dosing may facilitate self-administration of 
      tinzaparin in the outpatient setting.
FAU - Nutescu, Edith A
AU  - Nutescu EA
AD  - Department of Pharmacy Practice, College of Pharmacy, The University of Illinois 
      at Chicago, Chicago, IL, USA. enutescu@uic.edu
FAU - Shapiro, Nancy L
AU  - Shapiro NL
FAU - Feinstein, Helen
AU  - Feinstein H
FAU - Rivers, Christina W
AU  - Rivers CW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic/economics/methods/*statistics & numerical data
MH  - Heparin, Low-Molecular-Weight/economics/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Tinzaparin
MH  - Venous Thrombosis/*drug therapy/economics/metabolism
RF  - 56
EDAT- 2003/11/25 05:00
MHDA- 2004/04/14 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/04/14 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - 10.1345/aph.1D221 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2003 Dec;37(12):1831-40. doi: 10.1345/aph.1D221.